{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:19:55Z","timestamp":1791328795297,"version":"4.3.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Alefacept (anti-CD2) biological therapy selectively targets effector memory T cells (Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Circulating leukocytes were phenotyped in patients receiving alefacept for moderate to severe psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In all patients, this treatment caused a preferential decrease in effector memory T cells (CCR7<jats:sup>-<\/jats:sup>CD45RA<jats:sup>-<\/jats:sup>) (mean 63% reduction) for both CD4<jats:sup>+<\/jats:sup>and CD8<jats:sup>+<\/jats:sup>Tem, while central memory T cells (Tcm) (CCR7<jats:sup>+<\/jats:sup>CD45RA<jats:sup>-<\/jats:sup>) were less affected, and na\u00efve T cells (CCR7<jats:sup>+<\/jats:sup>CD45RA<jats:sup>+<\/jats:sup>) were relatively spared. Circulating CD8<jats:sup>+<\/jats:sup>effector T cells and Type 1 T cells (IFN-\u03b3-producing) were also significantly reduced.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Alefacept causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1479-5876-5-27","type":"journal-article","created":{"date-parts":[[2007,6,8]],"date-time":"2007-06-08T06:13:33Z","timestamp":1181283213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis"],"prefix":"10.1186","volume":"5","author":[{"given":"Francesca","family":"Chamian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Lee","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoko","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Gilleaudeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Sullivan-Whalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Cardinale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artemis","family":"Khatcherian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Novitskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut M","family":"Wittkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A","family":"Lowes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,6,7]]},"reference":[{"key":"187_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1067\/mjd.2002.120568","volume":"46","author":"JG Krueger","year":"2002","unstructured":"Krueger JG: The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002, 46: 1-23. 10.1067\/mjd.2002.120568.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"187_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.it.2004.03.006","volume":"25","author":"W Lew","year":"2004","unstructured":"Lew W, Bowcock AM, Krueger JG: Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and 'Type 1' inflammatory gene expression. Trends Immunol. 2004, 25 (6): 295-305. 10.1016\/j.it.2004.03.006.","journal-title":"Trends Immunol"},{"key":"187_CR3","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1046\/j.1523-1747.1999.00749.x","volume":"113","author":"LM Austin","year":"1999","unstructured":"Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG: The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol. 1999, 113: 752-759. 10.1046\/j.1523-1747.1999.00749.x.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"187_CR4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1056\/NEJM200107263450403","volume":"345","author":"CN Ellis","year":"2001","unstructured":"Ellis CN, Krueger GG: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. New England Journal of Medicine. 2001, 345 (4): 248-255. 10.1056\/NEJM200107263450403.","journal-title":"New England Journal of Medicine"},{"key":"187_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1146\/annurev.iy.09.040191.000331","volume":"9","author":"ML Dustin","year":"1991","unstructured":"Dustin ML, Springer TA: Role of lymphoctye adhesion receptors in transient interactions and cell locomotion. Annual Review of Immunology. 1991, 9: 27-66. 10.1146\/annurev.iy.09.040191.000331.","journal-title":"Annual Review of Immunology"},{"key":"187_CR6","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.4049\/jimmunol.163.11.5920","volume":"163","author":"K Crawford","year":"1999","unstructured":"Crawford K, Gabuzda D, Pantazopoulos V, Xu J, Clement C, Reinherz E, Alper CA: Circulating CD2+ monocytes are dendritic cells. J Immunol. 1999, 163: 5920-5928.","journal-title":"J Immunol"},{"key":"187_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/immu.200310010","volume":"33","author":"T Di Pucchio","year":"2003","unstructured":"Di Pucchio T, Lapenta C, Santini SM, Logozzi M, Parlato S, Belardelli F: CD2+\/CD14+ monocytes rapidly differentiate into CD83+ dendritic cells. Eur J Immunol. 2003, 33: 358-367. 10.1002\/immu.200310010.","journal-title":"Eur J Immunol"},{"key":"187_CR8","first-page":"1383","volume":"190","author":"MF Bacchmann","year":"1999","unstructured":"Bacchmann MF: CD2 sets quantitative thresholds in T cell activation. Journal of Immunology. 1999, 190: 1383-1391.","journal-title":"Journal of Immunology"},{"key":"187_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1084\/jem.178.1.211","volume":"178","author":"GT Miller","year":"1993","unstructured":"Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD, Wallner BP: Specific interaction of lymphocyte function associated antigen 3 with CD2 can inhibit T cell responses. Journal of Experimental Medicine. 1993, 178: 211-222. 10.1084\/jem.178.1.211.","journal-title":"Journal of Experimental Medicine"},{"key":"187_CR10","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/intimm\/8.7.1113","volume":"8","author":"D Lattine","year":"1995","unstructured":"Lattine D, De La Parra B, Nizet Y, Cornet A, Giovino-Barry V, Monroy R, White-Schart ME, Bazin H: An-anti-CD2 mAb induces immunosuppresssion and hyporesponsiveness of CD2+ human T cells in vitro. International Immunology. 1995, 8: 1113-1119. 10.1093\/intimm\/8.7.1113.","journal-title":"International Immunology"},{"key":"187_CR11","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.4049\/jimmunol.160.8.3797","volume":"160","author":"C Dumont","year":"1998","unstructured":"Dumont C, Deas O, Mollereau B, Hebib C, Giovino-Barry V, Bernard A, Hirsch F, Charpentier B, Senik A: Potent apoptotic signaling and subsequent unresponsiveness induced by a sigle CD2 mAb (BTI-332) in activated human peripheral T cells. Journal of Immunology. 1998, 160: 3797-3804.","journal-title":"Journal of Immunology"},{"key":"187_CR12","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/342811a0","volume":"342","author":"Y van Kooyk","year":"1989","unstructured":"van Kooyk Y, van de Weil-van Kemenade P, Weder P, Kuijers TW, Figdor CG: Enhancement of LFA-1-mediated cell adhesion by triggering through CD2 or CD3 on T lymphocytes. Nature. 1989, 342: 811-812. 10.1038\/342811a0.","journal-title":"Nature"},{"key":"187_CR13","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.4049\/jimmunol.152.6.2753","volume":"152","author":"GR Majeau","year":"1994","unstructured":"Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS: Mechanisms of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure\/Function analysis in vitro and in human CD2 transgenic mice. Journal of Immunology. 1994, 152: 2753-2767.","journal-title":"Journal of Immunology"},{"key":"187_CR14","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.4049\/jimmunol.168.9.4462","volume":"168","author":"AJ da Silva","year":"2002","unstructured":"da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu Y-M, Hochman PS: Alefacept, and immunomodulatory recombinant LFA-3\/IgG1 fusion protein, induces CD16 signaling and CD2\/CD16-dependant apoptosis of CD2+ cells. Journal of Immunology. 2002, 168: 4462-4471.","journal-title":"Journal of Immunology"},{"key":"187_CR15","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/44385","volume":"401","author":"F Sallusto","year":"1999","unstructured":"Sallusto F, Lenig D, RForster R, Lipp M, Lanzavecchia A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999, 401: 708-712. 10.1038\/44385.","journal-title":"Nature"},{"key":"187_CR16","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","volume":"22","author":"F Sallusto","year":"2004","unstructured":"Sallusto F, Geginat J, Lanzavecchia A: Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004, 22: 745-763. 10.1146\/annurev.immunol.22.012703.104702.","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"187_CR17","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1084\/jem.186.9.1407","volume":"186","author":"D Hamann","year":"1997","unstructured":"Hamann D, Baars PA, Rep MHG, Hooibrink B, JKertof-Garde SR, Klein MR, van Lier RAW: Phenotypic and functional separation of memory and effector human CD8+ T cells. Journal of Experimental Medicine. 1997, 186 (9): 1707-1418. 10.1084\/jem.186.9.1407.","journal-title":"Journal of Experimental Medicine"},{"issue":"12","key":"187_CR18","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/archderm.139.12.1563","volume":"139","author":"KB Gordon","year":"2003","unstructured":"Gordon KB, Vaishnaw AK, O'Gorman J, Haney J, Menter A: Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol. 2003, 139 (12): 1563-1570. 10.1001\/archderm.139.12.1563.","journal-title":"Arch Dermatol"},{"issue":"6","key":"187_CR19","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1073\/pnas.0409569102","volume":"102","author":"F Chamian","year":"2005","unstructured":"Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I, Khatcherian A, Novitskaya I, Wittkowski KM, Krueger JG: Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A. 2005, 102 (6): 2075-2080. 10.1073\/pnas.0409569102.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"187_CR20","doi-asserted-by":"publisher","first-page":"7442","DOI":"10.4049\/jimmunol.178.11.7442","volume":"178","author":"AS Haider","year":"2007","unstructured":"Haider AS, Lowes MA, Gardner H, Bandaru R, Darabi K, Chamian F, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I, Novitskaya I, Krueger JG: Novel insight into agonistic mechanism of alefacept in vivo: Differentially expressed genes may serve as biomarkers of response in psoriasis patients. J Immunol. 2007, 178 (11): 7442-9.","journal-title":"J Immunol"},{"issue":"5","key":"187_CR21","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S0190-9622(03)01836-X","volume":"49","author":"AB Gottlieb","year":"2003","unstructured":"Gottlieb AB, Casale TB, Frankel E, Goffe B, Lowe N, Ochs HD, Roberts JL, Washenik K, Vaishnaw AK, Gordon KB: CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol. 2003, 49 (5): 816-825. 10.1016\/S0190-9622(03)01836-X.","journal-title":"J Am Acad Dermatol"},{"key":"187_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0065-2776(02)80017-7","volume":"80","author":"B Grubeck-Loebenstein","year":"2002","unstructured":"Grubeck-Loebenstein B, Wick G: The aging of the immune system. Adv Immunol. 2002, 80: 243-284.","journal-title":"Adv Immunol"},{"key":"187_CR23","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/00007890-199208000-00018","volume":"54","author":"KD Chavin","year":"1992","unstructured":"Chavin KD, Lau HT, Bromberg JS: Prolongation of allograft and xenograft survival in mice by anti-CD2 monoclonal antibodies. Transplantation. 1992, 54: 286-291. 10.1097\/00007890-199208000-00018.","journal-title":"Transplantation"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-5-27.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T08:06:00Z","timestamp":1683878760000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-5-27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,7]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["187"],"URL":"https:\/\/doi.org\/10.1186\/1479-5876-5-27","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,7]]},"assertion":[{"value":"28 February 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"27"}}